59870-37-0

Upstream product

• 601-84-3 2,6-dibromobenzoic acid 
• 6575-12-8 2,6-dibromobenzonitrile 
• 96237-91-1 2,6-dibromobenzamide 
• 67713-23-9 2,6-dibromobenzaldehyde 
• 608-30-0 2,6-dibromoaniline 

Downstream Products

• 59189-52-5 2,6-dibromobenzophenone 
• 608-30-0 2,6-dibromoaniline 
• 1234380-77-8 2,6-dibromo-N-[2-(3-chloro-benzylsulfanyl)-ethyl]-benzamide 
• 1234380-78-9 2,6-dibromo-N-[2-(3-bromo-benzylsulfanyl)-ethyl]-benzamide 
• 1161124-35-1 C₁₇H₁₂Br₂N₂O₂ 
• 1214375-69-5 ethyl 2,6-dibromobenzoate 
• 96237-99-9 1-(2,6-dibromobenzoyl)-2-(p-nitrobenzoyl)hydrazine 
• 96237-91-1 2,6-dibromobenzamide 

Relevant academic research and scientific papers

Noncovalent Interactions in Ir-Catalyzed C-H Activation: L-Shaped Ligand for Para-Selective Borylation of Aromatic Esters

An efficient strategy for the para-selective borylation of aromatic esters is described. For achieving high para-selectivity, a new catalytic system has been developed modifying the core structure of the bipyridine. It has been proposed that the L-shaped ligand is essential to recognize the functionality of the oxygen atom of the ester carbonyl group via noncovalent interaction, which provides an unprecedented controlling factor for para-selective C-H activation/borylation.

Synthesis and biological evaluation of analogues of a novel inhibitor of β-amyloid secretion

A drug library of 17200 compounds was screened to select small molecules that inhibit the secretion of amyloid β peptide (Aβ), the major component of Alzheimer disease senile plaques, from a human neuronal cell line. Twenty-nine hits were validated that decreased Aβ secretion by >40% at 10 μM, for a 0.17% hit rate. A lead hit was selected for further study based on its activity and low cytotoxicity, and it was found to inhibit Aβ secretion through activation of the α-secretase pathway. Twenty-four commercially available and 53 synthesized analogues were analyzed for activity. Selected analogues were evaluated for biological stability by incubation with hepatoma cells and for transcellular permeability using Caco-2 cell monolayers. The analogue with the best permeability was evaluated in 2-month old amyloid precursor protein transgenic mice and found to acutely reduce cerebral Aβ levels by 40% after a single iv administration.

NOVEL COMPOUNDS

The present invention provides compounds of formula (I): a process for their preparation, to pharmaceutical compositions comprising the compounds and the preparation of said compositions, to intermediates and to use of the compounds for the manufacture of a medicament for therapeutic treatment, particularly for the treatment of inflammation, allergy and/or auto-immune conditions.

Substitution Reactions of Phenylated Aza-Heterocycles. Part 2. Bromination of Some 2,5-Diaryl-1,3,4-oxadiazoles

Electrophilic bromination of the title compounds may be achieved using either bromine in oleum, or bromine and potassium bromate in a sulphuric-acetic acid mixture.Under the milder reaction conditions provided by the latter, 2-(p-nitrophenyl)-5-phenyl-1,3,4-oxadiazole (2), the model compound used in this study, is mono- and di-brominated in the phenyl ring.In the first bromination step, all three monobromo-isomers are produced in appreciable amount.The orientation of the second bromination is controlled entirely by the first bromine and not by the oxadiazole substituent: this is confirmed by a separate study of the bromination of the three monobromo-compounds (3a-3c).